cGMP production and analysis of BG505 SOSIP.664, an extensively glycosylated, trimeric HIV‐1 envelope glycoprotein vaccine candidate

We describe the properties of BG505 SOSIP.664 HIV‐1 envelope glycoprotein trimers produced under current Good Manufacturing Practice (cGMP) conditions. These proteins are the first of a new generation of native‐like trimers that are the basis for many structure‐guided immunogen development programs...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Biotechnol Bioeng
Main Authors: Dey, Antu K., Cupo, Albert, Ozorowski, Gabriel, Sharma, Vaneet K., Behrens, Anna‐Janina, Go, Eden P., Ketas, Thomas J., Yasmeen, Anila, Klasse, Per J., Sayeed, Eddy, Desaire, Heather, Crispin, Max, Wilson, Ian A., Sanders, Rogier W., Hassell, Thomas, Ward, Andrew B., Moore, John P.
Formato: Artigo
Idioma:Inglês
Publicado: John Wiley and Sons Inc. 2017
Assuntos:
Articles
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5852640/
https://ncbi.nlm.nih.gov/pubmed/29150937
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/bit.26498
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares